GlassScriptPhysician profile
Mohammad Kazemi
NPI 1235556531
$16,202.89
in general payments reported to CMS, 2019-2025
12 companies · $10K in 2025
The $10K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.17 · 2022: $5,138 · 2023: $90.95 · 2024: $650 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,680 · Food and Beverage: $764 · Travel and Lodging: $427 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,680.00 |
| Food and Beverage | $764.41 |
| Travel and Lodging | $427.14 |
| Education | $134.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $9,293.21 | 2025 | Yescarta |
| Astrazeneca Pharmaceuticals LP | $3,560.00 | 2022-2025 | Enhertu |
| Genentech, INC. | $1,592.00 | 2022 | |
| Daiichi Sankyo INC. | $1,175.00 | 2024-2025 | Vanflyta, Enhertu |
| Pfizer INC. | $175.00 | 2025 | |
| Astellas Pharma US INC | $124.74 | 2024 | Xospata |
| Incyte Corporation | $90.95 | 2023 | |
| Adc Therapeutics America, INC. | $89.87 | 2025 | |
| Celgene Corporation | $73.54 | 2021-2025 | Breyanzi |
| Glaxosmithkline, LLC. | $28.58 | 2021-2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Kazemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.